News
CSLLY
29.81
+6.12%
1.72
Positive Report for CSL (CMXHF) from Jarden
TipRanks · 8h ago
Morgan Stanley Remains a Buy on CSL (CMXHF)
TipRanks · 1d ago
Bell Potter Keeps Their Hold Rating on CSL (CMXHF)
TipRanks · 1d ago
Citi Keeps Their Hold Rating on CSL (CMXHF)
TipRanks · 1d ago
CSL reports FY results
Seeking Alpha · 1d ago
Haemonetics rises after supply deal with CSL
Seeking Alpha · 1d ago
Macquarie Sticks to Its Hold Rating for CSL (CMXHF)
TipRanks · 2d ago
CSL (CMXHF) Receives a Buy from UBS
TipRanks · 2d ago
Here are the major earnings after the close Monday
Seeking Alpha · 2d ago
Weekly Report: what happened at CSLLY last week (0810-0814)?
Weekly Report · 2d ago
Is CSL An Unmissable Value Play?
Seeking Alpha · 6d ago
Weekly Report: what happened at CSLLY last week (0803-0807)?
Weekly Report · 08/10 10:03
Weekly Report: what happened at CSLLY last week (0727-0731)?
Weekly Report · 08/03 10:03
UBS Sticks to Its Buy Rating for CSL (CMXHF)
TipRanks · 07/31 13:36
Bell Potter Sticks to Their Hold Rating for CSL (CMXHF)
TipRanks · 07/31 00:05
CSL (CMXHF) Gets a Hold from Jefferies
TipRanks · 07/29 12:46
Weekly Report: what happened at CSLLY last week (0720-0724)?
Weekly Report · 07/27 10:06
Ord Minnett Reaffirms Their Hold Rating on CSL (CMXHF)
TipRanks · 07/23 00:35
Weekly Report: what happened at CSLLY last week (0713-0717)?
Weekly Report · 07/20 10:03
RBC Capital Sticks to Their Hold Rating for CSL (CMXHF)
TipRanks · 07/18 01:47
More
Webull provides a variety of real-time CSLLY stock news. You can receive the latest news about Csl Ltd through multiple platforms. This information may help you make smarter investment decisions.
About CSLLY
CSL Limited is an Australia-based biotechnology company. The Company’s areas of focus include rare and serious diseases, influenza vaccines and iron deficiency and nephrology. The Company’s segments include CSL Behring, CSL Seqirus and CSL Vifor. The CSL Behring segment manufactures, markets and distributes plasma products, gene therapies and recombinants. The CSL Seqirus segment manufactures, markets and distributes predominantly influenza related products and provides pandemic services to governments. The CSL Vifor segment manufactures, markets and distributes products in the therapeutic areas of iron deficiency and nephrology. Its CSL Plasma operates plasma collection networks, with approximately 325 plasma collection centers in the United States, Europe and China. The Company operates in Australia, the United States, Germany, the United Kingdom, Switzerland and China (including Hong Kong). Its products include Respreeza, Zemaira, HAEGARDA, KCENTRA, Hepatitis B, Evogam, and others.